Human Stem Cell-Derived Neural Progenitors and Neurons
AMSBIO has introduced a new range of neural progenitor cells, and cerebral cortical neurons, derived from human induced pluripotent stem (iPS) cells.
Despite the large investment and interest in neuroscience traditional methods of studying the human nervous system and disease pathogenesis and mechanisms required the generation of animal models. However, these methods are time consuming, costly and often fail to replicate the desired human pathologies and symptoms.
Using cutting-edge stem cell technologies to generate high purity human neural cells and neurons, AMSBIO is able to provide healthy and Alzheimer disease patient derived cerebral cortical neurons and neural progenitor cells. This accessible, in vitro human-based system offers a platform to build human cellular models to study conditions including Alzheimer’s, autism, epilepsy, traumatic brain injury and stroke. Derived using integration-free fully defined neural induction conditions, these cells are electrically active, form functional synapses in vitro and can be transplanted into animal models.
Available in industrial quantities, AMSBIO cerebral cortical neurons and neural progenitor cells are supplied with extensive functional and molecular characterization data. All products are supplied ready-made and remain viable in culture for months to facilitate reproducible and long-term studies. Cells from multiple donors are available for purchase allowing data comparison among biological replicates.
Alzheimer’s disease is the most common neurodegenerative disorder, now affecting more than 24 million people worldwide. Predicted to reach 100 million by 2050, this technology platform has been focused on providing both healthy and Alzheimer’s disease relevant human neurons derived from iPS cells to complement existing studies of this condition.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...